Feeds:
Posts
Comments

Posts Tagged ‘Hep C’

This Wednesday 05-02-2012 the topic is

Hepatitis C

our Guest speaker is:

Dr. Dominic Riganotti

Hepatitis C

  1. What is Hepatitis C?  What is it that is infective?
  2. What are the numbers…how many people are infected?….lets talk
  3. How could I get Hep C?  What’s the sources of infection?
  4. Disease stats…what happens to infected people?  Does everyone get sick?
  5. Is it just one type of virus?  Are some worse than others?
  6. What are the symptoms I can watch out for if I get infected?
  7. Where does the virus go in my body after it infects me?
  8. What’s the worst that could happen?
  9. What’s the treatment?
  10. How long is the treatment?
  11. Will it cure me?
  12. Will it make any of my other problems worse?
Wilton Manors Center for Infectious Disease & Immunology
Dr. Dominic Riganotti
Wilton Executive Suites
Infectious Diseases & Immunology
2312 Wilton Drive
HIV Care & Disease Management  
Wilton Manors, FL 33305
954.745.6874
Advertisements

Read Full Post »

This Wednesday 05-02-2012 the topic is

Hepatitis C

our Guest speaker is:

Dr. Dominic Riganotti

Hepatitis C

  1. What is Hepatitis C?  What is it that is infective?
  2. What are the numbers…how many people are infected?….lets talk
  3. How could I get Hep C?  What’s the sources of infection?
  4. Disease stats…what happens to infected people?  Does everyone get sick?
  5. Is it just one type of virus?  Are some worse than others?
  6. What are the symptoms I can watch out for if I get infected?
  7. Where does the virus go in my body after it infects me?
  8. What’s the worst that could happen?
  9. What’s the treatment?
  10. How long is the treatment?
  11. Will it cure me?
  12. Will it make any of my other problems worse?
Wilton Manors Center for Infectious Disease & Immunology
Dr. Dominic Riganotti
Wilton Executive Suites
Infectious Diseases & Immunology
2312 Wilton Drive
HIV Care & Disease Management  
Wilton Manors, FL 33305
954.745.6874

Read Full Post »

This Wednesday 05-02-2012 the topic is

Hepatitis C

our Guest speaker is:

Dr. Dominic Riganotti

Hepatitis C

  1. What is Hepatitis C?  What is it that is infective?
  2. What are the numbers…how many people are infected?….lets talk
  3. How could I get Hep C?  What’s the sources of infection?
  4. Disease stats…what happens to infected people?  Does everyone get sick?
  5. Is it just one type of virus?  Are some worse than others?
  6. What are the symptoms I can watch out for if I get infected?
  7. Where does the virus go in my body after it infects me?
  8. What’s the worst that could happen?
  9. What’s the treatment?
  10. How long is the treatment?
  11. Will it cure me?
  12. Will it make any of my other problems worse?
Wilton Manors Center for Infectious Disease & Immunology
Dr. Dominic Riganotti
Wilton Executive Suites
Infectious Diseases & Immunology
2312 Wilton Drive
HIV Care & Disease Management  
Wilton Manors, FL 33305
954.745.6874

Read Full Post »

I would like to announce and invite you to attend the ABCs of Hep and Health. On Thursday, June 23rd at 7pm (6:30 for refreshments) Infectious Disease Specialist Dr. James T. Dwyer and BioScript pharmacists Diona Libonati and Daniel Elmore will give the community an educational presentation examining Hepatitis A, B, & C, Co-infection with HIV and the latest treatments. See attachment. Please forward this information to your colleagues and clients. I look forward to seeing you all!

Michael Childers

Read Full Post »

From Poz magazine, there is an article in the March issue about Telaprevir, the first protease inhibitor (PI) for treatment of hepatitisC, that’s awaiting FDA approval. Telaprevir has proven effective in people with hard-to-treat hep-C genotype 1. In trials, adding telaprevir to standard hep-C treatment (peglated interferon plus ribavirin) shortened treatment time and cleared the virus.

Read Full Post »

HIV-Positive Men Who Bareback Should Have More Frequent Hep C Testing

Some key points from article:

A new study has found that 75 percent of new hepatitis C virus (HCV) infections in HIV-positive men occurred in those with no history of injection drug use (IDU)

Because of shared transmission routes, up to 30 percent of people with HIV in the United States also have chronic HCV infection. Chronic liver disease is a leading cause of death in people with HIV, and people coinfected with both HIV and HCV are also at a higher risk of death from a number of non-liver-related diseases, including kidney disease.

The majority of HCV cases in the United States are attributable to injection drug use, but there have been reports of HCV transmission in MSM who have no IDU history. Studies of these cases have suggested that HCV risk in these individuals is associated with various sexual practices, including unprotected anal intercourse, the use of sex toys, multiple partners and fisting.

In those studies, barebacking, coinfection with syphilis, and sex that is traumatic to the anus were highly associated with HCV infection in those with no IDU history.

Regular screening for HCV is crucial for two reasons.
1. Many who develop chronic HCV infections do not exhibit symptoms until they are quite ill years later.
2. When people are able to catch their HCV infection early—within a few weeks or months after exposure—HCV treatment is far more likely to work.

Read Full Post »

Human HIV drug trial near

CD4 T-cells are one measurement of the body’s immune system. Another cell that fights infections are called Natural Killer Cells (NK). These are a kind of white blood cell that play a major role in the rejection of tumors and cells infected with viruses.

But they don’t seem to attack cells infected with HIV and that has puzzled scientists for more than two decades. This article explains how HIV produces a protein called Vpu which basically neutralizes the NK cells preventing them from attacking the infected cells.

This new drug, BIT225, targets the Vpu protein of HIV which would then allow the NK cells to do their job. Which means this would be a new class of drugs in the fight against HIV.

“An Australian biomedical research company, Biotron Ltd, already has a drug that specifically targets the Vpu protein of HIV.

The discovery has excited Australian biomedical research company Biotron Ltd which has a drug that specifically targets the Vpu protein of HIV.

The drug has passed through early safety trials, and the company hopes to implement an efficacy trial with HIV-positive patients in the near future.

“This study is really important for Biotron,” said Biotron CEO Dr Michelle Miller.

“We have been working on developing drugs to target the Vpu protein of HIV for several years and, until recently, there has been very little known about exactly how Vpu works, despite good evidence that it is critical to the process of establishing HIV infections in specific cell types.”

From their company web site:

Based on the company info for Biotron, they have an efficacy trial in the works. Looks like there should be a definitive answer in about two years, to how well the treatment might work in humans.

This is a snip from their investor PDF. Looks like their avenue of research is at least promising (not just another ARV). Given the Rush Univ publication, I would think funding will now not be a problem. Because recent studies have shown that if you are adherent to your meds, the chance of resistance is extremely low, investors no longer see new HIV drugs worth the $$$. That’s why this recent news is so important. Otherwise this trial may have come up empty looking for scarce public funding.

• First-in-class new anti-HIV drug
• New mode of action – inhibits budding of virus from infected cells
• Targets HIV in viral reservoirs in vivo
• Reservoirs are last of the holy grail in HIV
• No existing drugs target this source of HIV in the body
• Eradication of reservoirs is essential for “cure” of HIV
• Phase Ib/IIa trial protocols finalised
• 12 – 20 subject trial in HIV+ patients
•Trial designed to demonstrate proof-of-concept i.e. can reduce HIV
loads in HIV-infected reservoir cells in man
• Expected to commence once funding in place

Additional links on related information:

News releases on the drug:

New class of drug in offering

http://www.biospectrumasia.com/content/251110AUS14722.asp

International study supports Biotron’s HIV drug approach

Biotron Presentation to Investors explaining drug’s importance

We will talk about this drug in the second half of the 12-15-2010 Wednesday group meeting.

-Steve

Read Full Post »

Older Posts »